Edge Therapeutics (EDGE) Trading Down 6.3%

Edge Therapeutics (NASDAQ:EDGE) traded down 6.3% during trading on Thursday . The stock traded as low as $1.15 and last traded at $1.20. 2,076,981 shares were traded during mid-day trading, an increase of 69% from the average session volume of 1,231,828 shares. The stock had previously closed at $1.28.

Several equities research analysts have commented on the stock. Credit Suisse Group reiterated an “outperform” rating and issued a $17.00 price objective on shares of Edge Therapeutics in a research note on Thursday, January 18th. BidaskClub upgraded shares of Edge Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, January 20th. Zacks Investment Research lowered shares of Edge Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 3rd. Finally, JMP Securities lowered shares of Edge Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Wednesday, March 28th.

The company has a debt-to-equity ratio of 0.28, a quick ratio of 6.92 and a current ratio of 6.92. The company has a market cap of $37.04, a P/E ratio of -0.68 and a beta of 3.98.

Edge Therapeutics (NASDAQ:EDGE) last posted its quarterly earnings data on Thursday, March 1st. The biotechnology company reported ($0.45) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by ($0.02).

In other Edge Therapeutics news, CEO Brian A. Leuthner sold 2,500 shares of the stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $13.14, for a total value of $32,850.00. Following the completion of the sale, the chief executive officer now owns 82,736 shares in the company, valued at approximately $1,087,151.04. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider R. Loch Macdonald sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $13.75, for a total transaction of $68,750.00. Following the sale, the insider now owns 590,602 shares of the company’s stock, valued at approximately $8,120,777.50. The disclosure for this sale can be found here. In the last quarter, insiders sold 17,500 shares of company stock valued at $257,800. Company insiders own 36.19% of the company’s stock.

Several hedge funds have recently modified their holdings of EDGE. SG Americas Securities LLC purchased a new stake in shares of Edge Therapeutics during the 4th quarter worth approximately $103,000. The Manufacturers Life Insurance Company increased its stake in shares of Edge Therapeutics by 26.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,114 shares of the biotechnology company’s stock worth $186,000 after purchasing an additional 3,764 shares during the last quarter. Wells Fargo & Company MN increased its stake in shares of Edge Therapeutics by 44.4% during the 3rd quarter. Wells Fargo & Company MN now owns 17,249 shares of the biotechnology company’s stock worth $186,000 after purchasing an additional 5,307 shares during the last quarter. Granite Investment Partners LLC purchased a new stake in shares of Edge Therapeutics during the 4th quarter worth approximately $296,000. Finally, Schwab Charles Investment Management Inc. increased its stake in shares of Edge Therapeutics by 11.8% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 89,594 shares of the biotechnology company’s stock worth $840,000 after purchasing an additional 9,424 shares during the last quarter. Institutional investors own 48.89% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This article was originally published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this article on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this article can be accessed at https://www.tickerreport.com/banking-finance/3377118/edge-therapeutics-edge-trading-down-6-3.html.

Edge Therapeutics Company Profile

Edge Therapeutics, Inc, a clinical-stage biotechnology company, discovers, develops, and seeks to commercialize hospital-based therapies for acute life-threatening neurological and other conditions. Its lead product includes EG-1962, a polymer-based microparticle used for the treatment of aneurysmal subarachnoid hemorrhage.

Receive News & Ratings for Edge Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edge Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Nordson Co.  Stake Boosted by Swiss National Bank
Nordson Co. Stake Boosted by Swiss National Bank
Reviewing NTT DATA Corp/ADR  and Computer Task Group
Reviewing NTT DATA Corp/ADR and Computer Task Group
Head-To-Head Contrast: United Technologies  vs. TAT Technologies
Head-To-Head Contrast: United Technologies vs. TAT Technologies
Critical Survey: Mobileye  versus American Software
Critical Survey: Mobileye versus American Software
Five9 Inc  Expected to Announce Earnings of $0.04 Per Share
Five9 Inc Expected to Announce Earnings of $0.04 Per Share
Henry Schein Inc  Shares Sold by Tredje AP fonden
Henry Schein Inc Shares Sold by Tredje AP fonden


© 2006-2018 Ticker Report. Google+.